Who
Peter Barrett
Director
Company insider
Files Form 4 as: Director, Obsidian Therapeutics; Director, Revvity; Director, Synlogic; Director and 10% owner, Larimar Therapeutics; Director, Vitae Pharmaceuticals; Director, Sciclone Pharmaceuticals; Director and 10% owner, Helicos Biosciences; Director, Momenta Pharmaceuticals.
In numbers
- Trades disclosed
- 168
- Buys
- 4
- Sells
- 13
- Bought
- $3.3M
- Sold
- $15.9M
- Companies
- 9
- Companies where not an officer
- 9
- First trade
- 23 Feb 2006
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | OBX Obsidian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,653 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | OBX Obsidian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,653 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,015 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,265 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,015 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,265 at $0.00 | filing |
| 30 Apr 2025filed 1 May 2025 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,074 at $0.00 | filing |
| 30 Apr 2025filed 1 May 2025 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,338 at $0.00 | filing |
| 1 May 2024filed 2 May 2024 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —977 at $0.00 | filing |
| 1 May 2024filed 2 May 2024 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —1,218 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | Synlogicoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,923 at $0.00 | filing |
| 22 Jun 2023filed 26 Jun 2023 | Synlogicoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 15 May 2023filed 17 May 2023 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —783 at $0.00 | filing |
| 15 May 2023filed 17 May 2023 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —955 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | Synlogicoption or derivative · Biotechnology | SEC FORM 4 Code A | —156,130 at $0.00 | filing |
| 9 Jun 2022filed 13 Jun 2022 | Synlogicoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 10 May 2022filed 12 May 2022 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 6 May 2022filed 9 May 2022 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —610 at $0.00 | filing |
| 6 May 2022filed 9 May 2022 | RVTY RevvityLife-science tools | SEC FORM 4 Code A | —744 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | Synlogicoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,334 at $0.00 | filing |
News
Alnylam Pharmaceuticals, Inc.: Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's DiseaseALNY · finanznachrichten.de · 23 Oct 2026Critical Survey: TScan Therapeutics (NASDAQ:TCRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · dailypolitical.com · 22 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) versus Oncocyte (NASDAQ:IMDX) Head to Head ComparisonALNY · dailypolitical.com · 21 Oct 2026Codexis (NASDAQ:CDXS) and Revvity (NYSE:RVTY) Head-To-Head ComparisonRVTY · themarketsdaily.com · 19 Oct 2026Rep. Gilbert Ray Cisneros, Jr. Sells Shares of Revvity Inc. (NYSE:RVTY)RVTY · tickerreport.com · 14 Oct 2026Revvity (NYSE:RVTY) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.RVTY · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Peter Barrett; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.